Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $51.00 at The Goldman Sachs Group

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target lifted by The Goldman Sachs Group from $46.00 to $51.00 in a report published on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other research firms have also recently issued reports on TARS. Jefferies Financial Group boosted their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim upped their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday. Finally, Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $66.33.

Tarsus Pharmaceuticals Trading Up 1.4 %

Shares of TARS stock opened at $48.00 on Monday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The firm’s fifty day simple moving average is $48.05 and its 200 day simple moving average is $48.98. The firm has a market capitalization of $2.02 billion, a P/E ratio of -12.60 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $78.34 million for the quarter, compared to the consensus estimate of $72.50 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,341 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares of the company’s stock, valued at approximately $2,687,458.53. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the transaction, the chief executive officer now owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Barclays PLC raised its holdings in Tarsus Pharmaceuticals by 345.9% during the 3rd quarter. Barclays PLC now owns 98,663 shares of the company’s stock worth $3,246,000 after purchasing an additional 76,538 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after buying an additional 420,057 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Tarsus Pharmaceuticals by 22.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 22,113 shares of the company’s stock worth $1,224,000 after buying an additional 4,008 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock valued at $63,499,000 after buying an additional 5,565 shares during the period. Finally, R Squared Ltd bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $53,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.